Shattuck Labs (NASDAQ:STTK – Get Free Report) and Kyntra Bio (NASDAQ:KYNB – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, profitability and dividends.
Profitability
This table compares Shattuck Labs and Kyntra Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Shattuck Labs | N/A | -46.46% | -43.56% |
| Kyntra Bio | 2,199.13% | N/A | -47.27% |
Risk and Volatility
Shattuck Labs has a beta of 1.21, indicating that its stock price is 21% more volatile than the S&P 500. Comparatively, Kyntra Bio has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500.
Earnings and Valuation
This table compares Shattuck Labs and Kyntra Bio”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Shattuck Labs | $1.00 million | 473.56 | -$48.81 million | ($0.51) | -9.12 |
| Kyntra Bio | $6.44 million | 2.16 | $183.45 million | $45.30 | 0.08 |
Kyntra Bio has higher revenue and earnings than Shattuck Labs. Shattuck Labs is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent recommendations for Shattuck Labs and Kyntra Bio, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Shattuck Labs | 1 | 0 | 9 | 3 | 3.08 |
| Kyntra Bio | 1 | 1 | 5 | 0 | 2.57 |
Shattuck Labs presently has a consensus price target of $13.70, indicating a potential upside of 194.62%. Kyntra Bio has a consensus price target of $36.80, indicating a potential upside of 969.77%. Given Kyntra Bio’s higher probable upside, analysts clearly believe Kyntra Bio is more favorable than Shattuck Labs.
Institutional & Insider Ownership
58.7% of Shattuck Labs shares are owned by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by insiders. Comparatively, 4.2% of Kyntra Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
About Shattuck Labs
Shattuck Labs, Inc. is a clinical-stage biotechnology company developing medicines that modulate the immune system to treat cancer. The company’s research has centered on biologic therapies designed to combine immune checkpoint inhibition with activation of immune cells. Its lead candidate, SL-172154, is an engineered fusion protein designed to block the CD47 “don’t eat me” signal and activate CD40, with the aim of promoting an antitumor immune response. Shattuck has evaluated the candidate in clinical studies for cancers including ovarian cancer and higher-risk myelodysplastic syndromes.
About Kyntra Bio
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.
Receive News & Ratings for Shattuck Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shattuck Labs and related companies with MarketBeat.com's FREE daily email newsletter.
